Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

DMC approves increased dosing frequency in phase II study of Brilacidin for COVID-19

April 6, 2021

VIR-7831 maintains neutralizing activity against SARS-CoV-2 California variant

April 6, 2021

Topline data from phase IIb portion of the phase IIb/III COVID-19 trial of ifenprodil

April 1, 2021

First volunteer dosed in phase I study of ALS-4 as treatment of MRSA

April 1, 2021

Daiichi Sankyo launches phase I study of DS-2319 for COVID-19

April 1, 2021

ChAdOx1 nCoV-19 vaccine does not protect against B.1.351 variant in South Africa trial

April 1, 2021

Qpex Biopharma initiates phase I study of QPX-7831

April 1, 2021

Enrollment open in phase I/II study of TP-102 bacteriophage therapy in diabetic foot ulcers

April 1, 2021

Pivotal topline data on BNT-162b2 in adolescents aged 12-15 years

March 31, 2021

Kamada reports phase I/II topline results on anti-SARS-CoV-2 plasma-derived IgG

March 31, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...